Toni Dubeau

1.8k total citations
35 papers, 943 citations indexed

About

Toni Dubeau is a scholar working on Genetics, Pathology and Forensic Medicine and Gastroenterology. According to data from OpenAlex, Toni Dubeau has authored 35 papers receiving a total of 943 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Genetics, 19 papers in Pathology and Forensic Medicine and 5 papers in Gastroenterology. Recurrent topics in Toni Dubeau's work include Chronic Lymphocytic Leukemia Research (35 papers), Lymphoma Diagnosis and Treatment (19 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). Toni Dubeau is often cited by papers focused on Chronic Lymphocytic Leukemia Research (35 papers), Lymphoma Diagnosis and Treatment (19 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). Toni Dubeau collaborates with scholars based in United States, Netherlands and China. Toni Dubeau's co-authors include Steven P. Treon, Jorge J. Castillo, Joshua Gustine, Kirsten Meid, Zachary R. Hunter, Lian Xu, Guang Yang, Nicholas Tsakmaklis, Maria Demos and Amanda Kofides and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Toni Dubeau

33 papers receiving 934 citations

Peers

Countries citing papers authored by Toni Dubeau

Since Specialization

Citations

This map shows the geographic impact of Toni Dubeau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toni Dubeau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toni Dubeau more than expected).

Fields of papers citing papers by Toni Dubeau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toni Dubeau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toni Dubeau. The network helps show where Toni Dubeau may publish in the future.

Co-authorship network of co-authors of Toni Dubeau

This figure shows the co-authorship network connecting the top 25 collaborators of Toni Dubeau. A scholar is included among the top collaborators of Toni Dubeau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toni Dubeau. Toni Dubeau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Joshua Gustine, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, (unknown), Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria Chan, Christopher J. Patterson, Andrew Keezer, Kirsten Meid, Toni Dubeau, Guang Yang, Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo	0
2	IBRUTINIB MONOTHERAPY PRODUCES LONG‐TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA. FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821). 2019 ·Hematological Oncology ·Steven P. Treon, Kirsten Meid, Joshua Gustine, Guang Yang, Lian Xu, Christopher J. Patterson, Irene M. Ghobrial, Jacob P. Laubach, Zachary R. Hunter, Toni Dubeau, Lia Palomba, Ranjana H. Advani, Jorge J. Castillo	12
3	CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib 2019 ·British Journal of Haematology ·Jorge J. Castillo, Lian Xu, Joshua Gustine, Andrew Keezer, Kirsten Meid, Toni Dubeau, Xia Liu, Maria Demos, Amanda Kofides, Nicholas Tsakmaklis, Jiaji G. Chen, Manit Munshi, Maria Luisa Guerrera, Gloria Chan, Christopher J. Patterson, Guang Yang, Zachary R. Hunter, Steven P. Treon	69
4	Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Jorge J. Castillo, John Allan, Tanya Siddiqi, Ranjana H. Advani, Andrew Keezer, Joshua Gustine, Kirsten Meid, Toni Dubeau, Jessica Lam, Lian Xu, Guang Yang, Zachary R. Hunter, Richard R. Furman, Matthew S. Davids, Steven P. Treon	8
5	Deepening of Response after Completing Rituximab-Containing Primary Therapy in Patients with Waldenstrom Macroglobulinemia 2018 ·Blood ·Jorge J. Castillo, Joshua Gustine, Toni Dubeau, Kirsten Meid, Andrew Keezer, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon	0
6	Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia 2018 ·Blood ·Gilad Itchaki, Toni Dubeau, Andrew Keezer, Kirsten Meid, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo	6
7	Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia 2017 ·Blood ·Jorge J. Castillo, Kirsten Meid, Joshua Gustine, Toni Dubeau, Patricia Severns, Steven P. Treon	2
8	Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial 2017 ·Blood ·Steven P. Treon, Kirsten Meid, Joshua Gustine, (unknown), Toni Dubeau, Patricia Severns, Guang Yang, Lian Xu, Christopher J. Patterson, Irene M. Ghobrial, Jacob P. Laubach, Zachary R. Hunter, Jorge J. Castillo, Maria Lia Palomba, Ranjana H. Advani	14
9	Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia 2017 ·Blood ·Kirsten Meid, Toni Dubeau, Patricia Severns, Joshua Gustine, Irene M. Ghobrial, Jorge J. Castillo, Steven P. Treon	13
10	Acquired Von Willebrand Disease in Patients with Waldenström Macroglobulinemia 2017 ·Blood ·Jorge J. Castillo, Joshua Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, Steven P. Treon	2
11	MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in Waldenstrom's Macroglobulinemia 2017 ·Blood ·Steven P. Treon, Zachary R. Hunter, Joshua Gustine, Kirsten Meid, Lian Xu, Xia Liu, Guang Yang, Manit Munshi, Robert Manning, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, (unknown), Gloria Chan, Christopher J. Patterson, Toni Dubeau, Patricia Severns, Jorge J. Castillo	1
12	Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline Waldenstrom Macroglobulinemia 2017 ·Blood ·Jorge J. Castillo, Joshua Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, Steven P. Treon	5
13	Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenström Macroglobulinemia 2017 ·Blood ·Joshua Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, Steven P. Treon, Jorge J. Castillo	2
14	MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival 2017 ·British Journal of Haematology ·Steven P. Treon, Joshua Gustine, Lian Xu, Robert Manning, Nicholas Tsakmaklis, Maria Demos, Kirsten Meid, Maria Luisa Guerrera, Manit Munshi, Gloria Chan, (unknown), Amanda Kofides, Christopher J. Patterson, Guang Yang, Xia Liu, Patricia Severns, Toni Dubeau, Zachary R. Hunter, Jorge J. Castillo	65
15	Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes 2016 ·British Journal of Haematology ·Josephine M. I. Vos, Joshua Gustine, Helmut G. Rennke, Zachary R. Hunter, Robert Manning, Toni Dubeau, Kirsten Meid, Monique C. Minnema, Marie José Kersten, Steven P. Treon, Jorge J. Castillo	56
16	Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia 2016 ·Blood ·Steven P. Treon, Nicholas Tsakmaklis, Kirsten Meid, Guang Yang, Jiaji G. Chen, Xia Liu, Jie Chen, Maria Demos, Christopher J. Patterson, Toni Dubeau, Joshua Gustine, Jorge J. Castillo, Ranjana H. Advani, Maria Lia Palomba, Lian Xu, Zachary R. Hunter	6
17	Histological transformation to diffuse large B‐cell lymphoma in patients with Waldenström macroglobulinemia 2016 ·American Journal of Hematology ·Jorge J. Castillo, Joshua Gustine, Kirsten Meid, Toni Dubeau, Zachary R. Hunter, Steven P. Treon	43
18	Lower Doses of Bendamustine Are Not Associated with Lower Response Rates in Previously Untreated Patients with Waldenström Macroglobulinemia 2016 ·Blood ·Jorge J. Castillo, Joshua Gustine, Kirsten Meid, Toni Dubeau, Irene M. Ghobrial, Steven P. Treon	2
19	Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia 2016 ·Blood ·Zachary R. Hunter, Lian Xu, Guang Yang, Nicholas Tsakmaklis, Josephine M. I. Vos, Xia Liu, Jie Chen, Robert Manning, Jiaji G. Chen, (unknown), Christopher J. Patterson, Joshua Gustine, Toni Dubeau, Jorge J. Castillo, Kenneth C. Anderson, (unknown), Steven P. Treon	65
20	The High Risk for Symptomatic Hyperviscosity in Patients with High Serum IgM Levels Can be Used to Support Initiation of Treatment in Waldenström Macroglobulinemia 2016 ·Blood ·Joshua Gustine, Kirsten Meid, (unknown), Toni Dubeau, Irene M. Ghobrial, Steven P. Treon, Jorge J. Castillo	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact